百可利在帕金森病中的神经保护作用机制研究进展

郝丹丹, 张垒, 郎卫红, 王玉敏

中国药学杂志 ›› 2022, Vol. 57 ›› Issue (7) : 524-529.

PDF(1093 KB)
中国药学杂志
PDF(1093 KB)
中国药学杂志 ›› 2022, Vol. 57 ›› Issue (7) : 524-529. DOI: 10.11669/cpj.2022.07.003
综述

百可利在帕金森病中的神经保护作用机制研究进展

  • 郝丹丹1, 张垒2, 郎卫红3, 王玉敏4*
作者信息 +

Current Advances in Understanding the Mechanism of Neuroprotective Effect of Baicalein in Parkinson′s Disease

  • HAO Dan-dan1, ZHANG Lei2, LANG Wei-hong3, WANG Yu-min4*
Author information +
文章历史 +

摘要

百可利(baicalein)是一种重要的黄酮类化合物,主要存在于黄芩的根中。研究表明,百可利在帕金森病的细胞模型和动物模型中具有神经保护作用,其能够抑制α-synuclein蛋白聚集、抗炎作用、调控Nrf2/ARE抗氧化防御体系、抑制铁损伤和抑制脂氧合酶。百可利可作为治疗帕金森病的潜在药物,笔者就百可利在帕金森病中的神经保护作用及其分子机制进行了综述。

Abstract

Baicalein, one of the important flavones, is mainly found in the root of scutellaria baicalensis Georgi. Certain lines of evidence suggest that baicalein has potent neuroprotective effects in vitro and in vivo on Parkinson′s disease (PD). Baicalein possesses a range of key pharmacological properties, such as inhibiting aggregation of α-synuclein (α-syn), anti-inflammatory properties, upregulating antioxidant enzymes, chelating excessive iron, and inhibiting lipoxygenase. The aim of the present study is to summarize the pharmacological neuroprotective actions of baicalein, and provide a comprehensive review of the molecular mechanism by which baicalein exert neuroprotective effect. The current review highlights could be useful to identify novel therapeutic agents in relation to the treatment of PD.

关键词

百可利 / 帕金森病 / 神经保护

Key words

baicalein / Parkinson′s disease / neuroprotection

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
郝丹丹, 张垒, 郎卫红, 王玉敏. 百可利在帕金森病中的神经保护作用机制研究进展[J]. 中国药学杂志, 2022, 57(7): 524-529 https://doi.org/10.11669/cpj.2022.07.003
HAO Dan-dan, ZHANG Lei, LANG Wei-hong, WANG Yu-min. Current Advances in Understanding the Mechanism of Neuroprotective Effect of Baicalein in Parkinson′s Disease[J]. Chinese Pharmaceutical Journal, 2022, 57(7): 524-529 https://doi.org/10.11669/cpj.2022.07.003
中图分类号： R741.05   

参考文献

[1] SOWNDHARARAJAN K, DEEPA P, KIM M, et al. Baicalein as a potent neuroprotective agent: A review [J]. Biomed Pharmacother, 2017, 95(11): 1021-1032.
[2] ZHAO Q, CHEN X Y, MARTIN C. Scutellaria baicalensis, the golden herb from the garden of Chinese medicinal plants [J]. Sci Bull (Beijing), 2016, 61 (18):1391-1398.
[3] DINDA B, SILSARMA I, DINDA M, et al. Oroxylum indicum (L.) Kurz, an important Asian traditional medicine: from traditional uses to scientific data for its commercial exploitation [J]. J Ethnopharmacol, 2015, 161(2): 255-278.
[4] LIU H, DONG Y, GAO Y, et al. The fascinating effects of baicalein on cancer: a review [J]. Int J Mol Sci, 2016, 17 (10):1681. doi:10.3390/ijms17101681.
[5] GOEDERT M. NEURODEGENERATION. Alzheimer′s and Parkinson′s diseases: the prion concept in relation to assembled Aβ, tau, and α-synuclein [J]. Science, 2015, 349 (6248):1255555.
[6] ZHU M, RAJAMANI S, KAYLOR J, et al. The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils [J]. J Biol Chem, 2004, 279 (26):26846-26857.
[7] LU J H, ARDAH M T, DURAIRAJAN S S, et al. Baicalein inhibits formation of α-synuclein oligomers within living cells and prevents Aβ peptide fibrillation and oligomerisation [J]. Chembiochem, 2011, 12 (4):615-624.
[8] JIANG M, PORAT-SHLIOM Y, PEI Z, et al. Baicalein reduces E46K alpha-synuclein aggregation in vitro and protects cells against E46K alpha-synuclein toxicity in cell models of familiar Parkinsonism [J]. J Neurochem, 2010, 114 (2):419-429.
[9] HU Q, UVERSKY V N, HUANG M, et al. Baicalein inhibits α-synuclein oligomer formation and prevents progression of α-synuclein accumulation in a rotenone mouse model of Parkinson′s disease [J]. Biochim Biophys Acta, 2016, 1862 (10):1883-1890.
[10] CARUANA M, NEUNER J, HÖGEN T, et al. Polyphenolic compounds are novel protective agents against lipid membrane damage by α-synuclein aggregates in vitro [J]. Biochim Biophys Acta, 2012, 1818 (11):2502-2510.
[11] HUNG K C, HUANG H J, WANG Y T, et al. Baicalein attenuates α-synuclein aggregation, inflammasome activation and autophagy in the MPP+-treated nigrostriatal dopaminergic system in vivo [J]. J Ethnopharmacol, 2016, 194(12): 522-529.
[12] LEE Y, LEE S, CHANG S C, et al. Significant roles of neuroinflammation in Parkinson′s disease: therapeutic targets for PD prevention [J]. Arch Pharm Res, 2019, 42 (5):416-425.
[13] HASSANZADEH K, RAHIMMI A. Oxidative stress and neuroinflammation in the story of Parkinson′s disease: Could targeting these pathways write a good ending? [J]. J Cell Physiol, 2018, 234 (1):23-32.
[14] LI F Q, WANG T, PEI Z, et al. Inhibition of microglial activation by the herbal flavonoid baicalein attenuates inflammation-mediated degeneration of dopaminergic neurons [J]. J Neural Transm (Vienna), 2005, 112 (3):331-347.
[15] LEE E, PARK H R, JI S T, et al. Baicalein attenuates astroglial activation in the 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine-induced Parkinson′s disease model by downregulating the activations of nuclear factor-κB, ERK, and JNK [J]. J Neurosci Res, 2014, 92 (1):130-139.
[16] CHENG Y, HE G, MU X, et al. Neuroprotective effect of baicalein against MPTP neurotoxicity: behavioral, biochemical and immunohistochemical profile [J]. Neurosci Lett, 2008, 441 (1):16-20.
[17] HE X, WEI Z, ZHOU E, et al. Baicalein attenuates inflammatory responses by suppressing TLR4 mediated NF-κB and MAPK signaling pathways in LPS-induced mastitis in mice [J]. Int Immunopharmacol, 2015, 28 (1):470-476.
[18] CHEN Y C, SHEN S C, CHEN L G, et al. Wogonin, baicalin, and baicalein inhibition of inducible nitric oxide synthase and cyclooxygenase-2 gene expressions induced by nitric oxide synthase inhibitors and lipopolysaccharide [J]. Biochem Pharmacol, 2001, 61 (11):1417-1427.
[19] YAN J J, DU G H, QIN X M, et al. Baicalein attenuates the neuroinflammation in LPS-activated BV-2 microglial cells through suppression of pro-inflammatory cytokines, COX2/NF-κB expressions and regulation of metabolic abnormality [J]. Int Immunopharmacol, 2020, 79(2): 106092. Doi:10.1016/j.intimp.2019.106092.
[20] RUI W, LI S, XIAO H, et al. Baicalein attenuates neuroinflammation by inhibiting NLRP3/caspase-1/GSDMD pathway in MPTP induced mice model of parkinson′s disease [J]. Int J Neuropsychopharmacol, 2020, 23 (11):762-773.
[21] IM H I, JOO W S, NAM E, et al. Baicalein prevents 6-hydroxydopamine-induced dopaminergic dysfunction and lipid peroxidation in mice [J]. J Pharmacol Sci, 2005, 98 (2):185-189.
[22] MU X, HE G R, YUAN X, et al. Baicalein protects the brain against neuron impairments induced by MPTP in C57BL/6 mice [J]. Pharmacol Biochem Behav, 2011, 98 (2):286-291.
[23] ZHENG Z V, CHEUNG C Y, LYU H, et al. Baicalein enhances the effect of low dose Levodopa on the gait deficits and protects dopaminergic neurons in experimental Parkinsonism [J]. J Clin Neurosci, 2019, 64(6): 242-251.
[24] HEMMATI-DINARVAND M, SAEDI S, VALILO M, et al. Oxidative stress and Parkinson′s disease: conflict of oxidant-antioxidant systems [J]. Neurosci Lett, 2019, 709(9): 134296.
[25] LEE I K, KANG K A, ZHANG R, et al. Mitochondria protection of baicalein against oxidative damage via induction of manganese superoxide dismutase [J]. Environ Toxicol Pharmacol, 2011, 31 (1):233-241.
[26] ZHANG Z, CUI W, LI G, et al. Baicalein protects against 6-OHDA-induced neurotoxicity through activation of Keap1/Nrf2/HO-1 and involving PKCα and PI3K/AKT signaling pathways [J]. J Agric Food Chem, 2012, 60 (33):8171-8182.
[27] MOCHIZUKI H, CHOONG C J, BABA K. Parkinson′s disease and iron [J]. J Neural Transm (Vienna), 2020, 127 (2):181-187.
[28] SCHNEIDER S A. Neurodegeneration with Brain Iron Accumulation [J]. Curr Neurol Neurosci Rep, 2016, 16 (1):9.
[29] GAO D, SAKURAI K, CHEN J, et al. Protection by baicalein against ascorbic acid-induced lipid peroxidation of rat liver microsomes [J]. Res Commun Mol Pathol Pharmacol, 1995, 90 (1):103-114.
[30] KANG K H, LIOU H H, HOUR M J, et al. Protection of dopaminergic neurons by 5-lipoxygenase inhibitor [J]. Neuropharmacology, 2013, 73(10): 380-387.
[31] LI Z, CHOI D Y, SHIN E J, et al. Phenidone protects the nigral dopaminergic neurons from LPS-induced neurotoxicity [J]. Neurosci Lett, 2008, 445 (1):1-6.
[32] DESCHAMPS J D, KENYON V A, HOLMAN T R. Baicalein is a potent in vitro inhibitor against both reticulocyte 15-human and platelet 12-human lipoxygenases [J]. Bioorg Med Chem, 2006, 14 (12):4295-4301.
[33] LEE H J, NOH Y H, LEE D Y, et al. Baicalein attenuates 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells [J]. Eur J Cell Biol, 2005, 84 (11):897-905.
[34] MU X, HE G, CHENG Y, et al. Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro [J]. Pharmacol Biochem Behav, 2009, 92 (4):642-648.
[35] LI X X, HE G R, MU X, et al. Protective effects of baicalein against rotenone-induced neurotoxicity in PC12 cells and isolated rat brain mitochondria [J]. Eur J Pharmacol, 2012, 674 (2-3):227-233.
[36] SONG J X, CHOI M Y, WONG K C, et al. Baicalein antagonizes rotenone-induced apoptosis in dopaminergic SH-SY5Y cells related to Parkinsonism [J]. Chin Med, 2012, 7 (1):1.
[37] KUANG L, CAO X, LU Z. Baicalein protects against rotenone-induced neurotoxicity through induction of autophagy [J]. Biol Pharm Bull, 2017, 40 (9):1537-1543.
[38] LI X, ZHANG G, NIE Q, et al. Baicalein blocks α-synuclein secretion from SN4741 cells and facilitates α-synuclein polymerization to big complex [J]. Neurosci Lett, 2017, 655(8): 109-114.
[39] WANG S F, LIU L F, WU M Y, et al. Baicalein prevents 6-OHDA/ascorbic acid-induced calcium-dependent dopaminergic neuronal cell death [J]. Sci Rep, 2017, 7 (1):8398.
[40] WANG Y H, YU H T, PU X P, et al. Baicalein prevents 6-hydroxydopamine-induced mitochondrial dysfunction in SH-SY5Y cells via inhibition of mitochondrial oxidation and up-regulation of DJ-1 protein expression [J]. Molecules, 2013, 18 (12):14726-14738.
[41] YU X, HE G R, SUN L, et al. Assessment of the treatment effect of baicalein on a model of Parkinsonian tremor and elucidation of the mechanism [J]. Life Sci, 2012, 91 (1-2):5-13.
[42] ZHANG X, DU L, ZHANG W, et al. Therapeutic effects of baicalein on rotenone-induced Parkinson′s disease through protecting mitochondrial function and biogenesis [J]. Sci Rep, 2017, 7 (1):9968. Doi:10.1038/s41598-017-07442-y.
[43] ZHANG X, YANG Y, DU L, et al. Baicalein exerts anti-neuroinflammatory effects to protect against rotenone-induced brain injury in rats [J]. Int Immunopharmacol, 2017, 50(9): 38-47.
[44] XUE X, LIU H, QI L, et al. Baicalein ameliorated the upregulation of striatal glutamatergic transmission in the mice model of Parkinson′s disease [J]. Brain Res Bull, 2014, 103: 54-59.
[45] GAO L, LI C, YANG R Y, et al. Ameliorative effects of baicalein in MPTP-induced mouse model of Parkinson′s disease: A microarray study [J]. Pharmacol Biochem Behav, 2015, 133(6): 155-163.
[46] CHEN T, LI Y, LI C, et al. Pluronic P85/F68 micelles of baicalein could interfere with mitochondria to overcome MRP2-Mediated efflux and offer improved anti-parkinsonian activity [J]. Mol Pharm, 2017, 14 (10):3331-3342.
[47] ZHAO W Z, WANG H T, HUANG H J, et al. Neuroprotective effects of baicalein on acrolein-induced neurotoxicity in the nigrostriatal dopaminergic system of rat brain [J]. Mol Neurobiol, 2018, 55 (1):130-137.
[48] PANG H, XUE W, SHI A, et al. Multiple-ascending-dose pharmacokinetics and safety evaluation of baicalein chewable tablets in healthy Chinese volunteers [J]. Clin Drug Investig, 2016, 36 (9):713-724.
[49] LI M, SHI A, PANG H, et al. Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects [J]. J Ethnopharmacol, 2014, 156(10): 210-215.
[50] XUE W, SHI A X, LI M, et al. Tolerability of baicalein chewable tablets in chinese healthy volunteers:a single-dose dose-escalating study [J]. Chin Pharm J (中国药学杂志), 2015, 50 (22):1987-1991.
[51] DONG R, LI L, GAO H, et al. Safety, tolerability, pharmacokinetics, and food effect of baicalein tablets in healthy Chinese subjects: a single-center, randomized, double-blind, placebo-controlled, single-dose phase I study [J]. J Ethnopharmacol, 2021, 274(6): 114052. Doi:10.1016/j.jep.2021.114052.

基金

国家自然科学基金项目资助(81260196,81450036); 内蒙古自治区高等学校青年科技英才支持计划资助(NJYT-17-B23); 内蒙古自治区高校科研项目资助(NJZY19218); 内蒙古自然科学基金项目资助(2020MS08175,2021MS08131,2021LHMS08024); 内蒙古草原英才计划项目资助; 航天医科科研基金资助项目资助(2020YK02,2021YK05)
PDF(1093 KB)

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉